Source: Investing.com ↗

Mizuho reiterates Sarepta stock rating after Novartis trial miss

|

Translation unavailable. Please try again.

Original report

Read the original report on Investing.com ↗

Recommended markets

No specific asset was identified in this report; browse live USDT reference pairs.

Browse markets →

BTC/USDT

$65,533.09

-4.91%

USDC/USDT

$1.00

-0.00%

ETH/USDT

$1,828.96

-5.84%

SOL/USDT

$72.13

-9.99%

ZEC/USDT

$850.75

-10.10%